Evidence map›Paper›PMID 30546099›Full record

ReviewNature microbiology2019

Tracking virus outbreaks in the twenty-first century.

Nathan D Grubaugh, Jason T Ladner, Philippe Lemey, Oliver G Pybus, Andrew Rambaut, Edward C Holmes, Kristian G Andersen

Abstract readReview
In one paragraph

Review in Nature microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 248 papers.

0numbers the graph read from it
0cells of the map it votes in
248citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

248 citing papers in PubMed.

  1. Trial
  2. Review
  3. A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026
    Review
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Global Genomic Surveillance: On-The-Ground Responses.Current topics in microbiology and immunology · 2026
    Review
  20. Review

188 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Nathan D GrubaughDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
Jason T LadnerPathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, USA. jason.ladner@nau.edu.ORCID http://orcid.org/0000-0001-7751-4366
Philippe LemeyDepartment of Microbiology and Immunology, Rega Institute, KU Leuven - University of Leuven, Leuven, Belgium.
Oliver G PybusDepartment of Zoology, University of Oxford, Oxford, UK.
Andrew RambautInstitute of Evolutionary Biology, University of Edinburgh, Edinburgh, UK. a.rambaut@ed.ac.uk.ORCID http://orcid.org/0000-0003-4337-3707
Edward C HolmesMarie Bashir Institute for Infectious Diseases and Biosecurity, School of Life and Environmental Sciences and Sydney Medical School, Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia. edward.holmes@sydney.edu.au.ORCID http://orcid.org/0000-0001-9596-3552
Kristian G AndersenDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-6431-5982

Funding

Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Kristian Graugaard Andersen · 2018 to 2026
$32.0M
Scripps Translational Science InstituteUL1TR002550 · NCATS · SCRIPPS RESEARCH INSTITUTE, THE · PI TOPOL, ERIC JEFFREY · 2018 to 2022
$28.9M
PATHOGENESIS AND IMMUNOLOGY OF DISEASET32AI007244 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI NEMAZEE, DAVID · 1985 to 2022
$8.8M
Analysis of Zika virus emergence and functional evolution in the AmericasR21AI137690 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ANDERSEN, KRISTIAN GRAUGAARD · 2018 to 2019
$547k
NCATS NIH HHS UL1 TR002550NIAID NIH HHS HHSN272201400048CNIAID NIH HHS R21 AI137690NIAID NIH HHS T32 AI007244NIAID NIH HHS U19 AI135995Wellcome Trust
6 · The paper itself

Abstract

Emerging viruses have the potential to impose substantial mortality, morbidity and economic burdens on human populations. Tracking the spread of infectious diseases to assist in their control has traditionally relied on the analysis of case data gathered as the outbreak proceeds. Here, we describe how many of the key questions in infectious disease epidemiology, from the initial detection and characterization of outbreak viruses, to transmission chain tracking and outbreak mapping, can now be much more accurately addressed using recent advances in virus sequencing and phylogenetics. We highlight the utility of this approach with the hypothetical outbreak of an unknown pathogen, 'Disease X', suggested by the World Health Organization to be a potential cause of a future major epidemic. We also outline the requirements and challenges, including the need for flexible platforms that generate sequence data in real-time, and for these data to be shared as widely and openly as possible.

Indexed as

Communicable Diseases, EmergingContact TracingDisease OutbreaksGenome, ViralHumansInformation DisseminationViruses

Identifiers

PMID30546099
PMCPMC6345516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.